Liquid biopsy, specifically circulating cell-free DNA (cfDNA), has emerged as a powerful tool for cancer early diagnosis, prognosis, and treatment monitoring over a wide range of cancer types.

In 107 patients, 48.6% of those who received unusual or nonreportable clinical cfDNA-sequencing results had an occult cancer, reported Diana W. Bianchi, MD, of the Eunice Kennedy Shriver National ...

SCLC generates particularly high levels of cfDNA, likely owing to the highly metastatic nature of this cancer type. Dr. MacPherson explained that cell-free, circulating tumor DNA (ctDNA) is now ...

Download this article to explore how scientists engaged in early cancer diagnostics research can maximize methylation sequencing workflows using cutting edge methylation detection and custom capture ...

Liquid biopsies are tests that detect signs of cancer through a simple blood draw. Unlike traditional biopsies, which require removing a piece of tissue, a liquid biopsy typically looks for mutations ...

The funding round saw participation from new investors Bold Capital and Bold Longevity Growth Fund, alongside previous investors.

Nucleosome patterns in cfDNA discern maternal–fetal tissue composition and early tissue dysfunction in those who develop preeclampsia. Credit: Nature Medicine (2025). DOI: 10.1038/s41591-025-03509-w ...

Innovations in cell-free gene synthesis decrease turnaround times for obtaining full-length, complex, NGS-verified DNA from weeks or months to as few as 6-8 business days. Cell-free DNA speeds ...